Core Viewpoint - Ziff Davis investors experienced significant losses as the company's reported financial metrics obscured its actual performance, leading to a stock decline of over 10% following the Q4 2025 earnings report [1] Financial Performance - For the year 2025, Ziff Davis reported adjusted EBITDA of $495.1 million and adjusted diluted EPS of $6.63, both figures falling below the company's projections [1] - The company's Q4 2025 revenue declined by 1.5% year-over-year to $406.7 million, with adjusted EPS missing both consensus and internal projections [1] Communication and Reporting - Throughout 2025, Ziff Davis emphasized adjusted EBITDA and adjusted diluted EPS as key performance indicators during earnings presentations and calls [1] - The CFO reported an adjusted diluted EPS of $1.24 during the Q2 2025 earnings call, attributing it to higher adjusted EBITDA and lower diluted shares outstanding, which contrasted with the GAAP results that included foreign-exchange-related losses [1]

Financial Performance - Wyndham Hotels & Resorts reported a net loss of $60 million in Q4 2025, compared to a net income of $85 million in Q4 2024 [1] - For the full year 2025, net income decreased by 33% to $193 million from $289 million in 2024, primarily due to non-cash impairment and related charges [1] - Adjusted EBITDA for Q4 2025 fell by 2% to $165 million from $168 million in Q4 2024, while for the full year, it increased by 3% to $718 million compared to $694 million in 2024 [1] Earnings Per Share - Adjusted diluted earnings per share (EPS) for Q4 2025 decreased by 11% to $0.93 from $1.04 in Q4 2024 [2] - For the full year 2025, adjusted diluted EPS grew by 6% to $4.58 from $4.33 in 2024, while reported diluted EPS fell by 31% to $2.50 from $3.61, mainly due to impairment charges [2] Growth and Development - The company opened a record 72,000 rooms globally, achieving 4% net room growth and expanding its development pipeline to a record 259,000 rooms [2] - Despite negative US RevPAR pressure, full-year comparable-basis adjusted EBITDA and adjusted EPS grew by 4% and 6%, respectively, with adjusted free cash flow exceeding $430 million and nearly $400 million returned to shareholders [3] Future Guidance - For full-year 2026, Wyndham Hotels has guided adjusted EBITDA of $730 million to $745 million, adjusted diluted EPS of $4.62 to $4.80, and fee-related revenues of $1.46 billion to $1.49 billion [3] - Global RevPAR growth is projected to be between -1.5% and 0.5% on a constant currency basis, with room growth expected at 4.0% to 4.5% [4] Dividend and Expansion - The Board of Directors approved a 5% increase in the quarterly cash dividend to $0.43 per share [4] - Wyndham has expanded its presence in South Korea by launching its first managed hotel and initiating two new development projects [4]

Core Insights - Abbott's third-quarter results for 2025 show a total worldwide sales increase of 6.9% to $11.369 billion compared to $10.635 billion in the same quarter of 2024 [23] - The company reported a GAAP diluted EPS of $0.94 and an adjusted diluted EPS of $1.30, reflecting a 7.4% increase from the previous year [7][24] - Abbott reaffirms its full-year 2025 organic sales growth guidance of 7.5% to 8.0%, excluding COVID-19 testing-related sales [17] Financial Performance - Total reported sales for the third quarter were $11.369 billion, with U.S. sales at $4.299 billion and international sales at $7.070 billion [4] - The organic sales growth was 5.5%, or 7.5% when excluding COVID-19 testing-related sales [7] - Year-to-date sales for the first nine months of 2025 reached $32.869 billion, a 6.1% increase from $30.976 billion in the same period of 2024 [24] Segment Performance - Nutrition segment sales for Q3 2025 were $2.153 billion, with U.S. sales declining by 6.5% and international sales increasing by 13.3% [6][9] - Diagnostics segment reported sales decreased by 6.6% to $2.253 billion, with a notable decline in COVID-19 testing sales from $265 million in Q3 2024 to $69 million in Q3 2025 [10][11] - Medical Devices segment sales increased by 14.8% to $5.448 billion, driven by strong growth in Diabetes Care and other areas [15][16] Guidance and Future Outlook - Abbott has narrowed its full-year 2025 adjusted diluted EPS guidance range to $5.12 to $5.18, indicating double-digit growth at the midpoint [7][17] - The company received regulatory approvals for new products, including TriClip and an expanded indication for the Navitor TAVI system, which are expected to contribute to future growth [7] Dividend Information - Abbott declared a quarterly dividend of $0.59 per share, marking the 407th consecutive quarterly dividend, with a history of increasing dividends for 53 consecutive years [19]